NRXP
NRX Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$102.18M
P/E Ratio
—
EPS
$-1.34
Beta
2.02
52W High
$3.84
52W Low
$1.62
50-Day MA
$2.23
200-Day MA
$2.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
23.75
PEG Ratio
—
About NRX Pharmaceuticals Inc
NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company, develops new treatments for the treatment of life-threatening central nervous system disorders and lung diseases. The company is headquartered in Wilmington, Delaware.
Fundamentals
| Revenue (TTM) | $1.23M |
| Gross Profit (TTM) | 720,000 |
| EBITDA | $-16.12M |
| Operating Margin | -467.30% |
| Return on Equity | -683.00% |
| Return on Assets | -121.80% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $-0.50 |
| Price-to-Book | 2.90 |
| Price-to-Sales (TTM) | 83.41 |
| EV/Revenue | 77.56 |
| EV/EBITDA | -0.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.07M |
| Float | $24.24M |
| % Insiders | 8.30% |
| % Institutions | 25.54% |
Historical Volatility
HV 10-Day
62.64%
HV 20-Day
97.63%
HV 30-Day
106.43%
HV 60-Day
92.09%
HV Rank
96.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($38.25 target)
4
BuyMore HEALTHCARE Stocks
Data last updated: 5/5/2026